Virtual Library
Start Your Search
Xiaofei Wang
Author of
-
+
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.01-29 - Lung Adenocarcinoma Harboring EGFR-19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy (Now Available) (ID 674)
08:00 - 18:00 | Presenting Author(s): Xiaofei Wang
- Abstract
Background
Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails due to the emergence of T790M mutation. Though Osimertinib is effective in overcoming EGFR T790M by targeting Cys797 via covalent bonding, their efficacy is again limited due to the emergence of C797S mutation.
Method
The study showed one patient with advanced NSCLC treated with targeted therapy, who developed acquired drug resistance to 1st to 3rd generation of EGFR-TKIs. The medical records and imaging studies of the patient were retrospectively reviewed under the approval of the institutional review board and the waiver the informed consent. The study was conducted with agreement of the patient herself.
Result
This is one of the earliest report which describe cis mutations of T790 and C797s as the resistance mechanism observed in circulating tumor DNA (ctDNA) from a patient with initial response followed by progression on osimertinib and sucesesfuly treated with Brigatinib + Erbitux.
Conclusion
This case report,as to our knoweledge, is the first clinical evidence of efficacy using a combination of brigatinib and cetuximab to target concomitant EGFR-T790M and C797S in cis.
